Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

CTx 001 - Complement Therapeutics

Next Previous
X
Search
Drug Profile

CTx 001 - Complement Therapeutics

Alternative Names: CTx-001 - Complement Therapeutics

Latest Information Update: 21 Apr 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator University of Manchester
  • Developer Complement Therapeutics
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Dry age-related macular degeneration

Most Recent Events

  • 21 Apr 2023 Complement Therapeutics plans a phase I/II trial for Geographic atrophy due to dry age-related macular degeneration in the UK in 2024 (Complement Therapeutics, April 2023)
  • 17 Apr 2023 Complement Therapeutics plans a phase Ib clinical proof of concept trial for Geographic atrophy
  • 01 Nov 2022 CTx 001 receives 'Innovation Passport' designation under the new accelerated Innovative Licensing and Access Pathway (ILAP) for Geographic atrophy in the United Kingdom

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top